Strug­gling gene ther­a­py pi­o­neer uniQure brings out the ax, chop­ping pro­grams and staffers in over­haul

UniQure was able to snare the world’s first ap­proval for a gene ther­a­py. But it wasn’t able to cash in. And with its top pipeline pro­grams strug­gling against heavy­weight com­pe­ti­tion, the Dutch/US biotech $QURE to­day took out the ax and start­ed to chop away at its R&D struc­ture in search of some big cost sav­ings.

The ax is be­ing aimed at R&D in The Nether­lands as uniQure plans to con­sol­i­date man­u­fac­tur­ing in the US, where it has fa­cil­i­ties in Lex­ing­ton, MA. Up to 60 jobs, a quar­ter of its work­force, will be cut in the re­or­ga­ni­za­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.